{"ATC Code":"N - Nervous system","Abbreviation":"","Aliases":["Frosinor","Casbol","Motivan","PaxPar","Paroxetina","Paxetil","Paroxetinum","Arketis","Besitram","Daparox"],"Biological Half-Life":"The mean elimination half-life of paroxetine is about 21 hours. In healthy young subjects, mean elimination half-life was found to be 17.3 hours.","Boiling Point":"451.7±45.0","CAS":"61869-08-7","ChEBI":"CHEBI:7936","ChEMBL":"CHEMBL490","ChemicalClasses":["piperidine"],"Chirality":"absolute","Classes":null,"Dosing Info":[{"Method":"Oral","Tiers":{"Common":{"Lower":17.5,"Upper":20},"Heavy":{"Lower":30,"Upper":40},"Light":{"Lower":10,"Upper":17.5},"Strong":{"Lower":20,"Upper":30},"Threshold":{"Lower":1,"Upper":10}},"Unit":"mg"}],"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Antidepressive Agents; Serotonin Uptake Inhibitors","Drug Indication":"Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause. Off-label, paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome (IBS).","Drug Warnings":"/BOXED WARNING/  SUICIDALITY AND ANTIDEPRESSANT DRUGS. Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of Paxil or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Paxil is not approved for use in pediatric patients.","DrugClasses":["antidepressant","depressant"],"Esters":["acetate"],"European Community (EC) Number":"600-962-7","FDA Pharmacological Classification":"41VRH5220H","FullSalts":["Paroxetine mesylate","Paroxetine maleate","Paroxetine acetate","Paroxetine hydrochloride"],"HMDB ID":"HMDB0014853","HeavyAtomCount":24,"Human Drugs":"Antidepressants -\u003e Selective serotonin reuptake inhibitors (SSRI)","IUPACName":"(3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine","InChI":"InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1","InChIKey":"AHOUBRCZNHFOSL-YOEHRIQHSA-N","MeSH Pharmacological Classification":"Compounds that specifically inhibit the reuptake of serotonin in the brain. (See all compounds classified as Selective Serotonin Reuptake Inhibitors.)","Melting Point":"120-138","MolecularFormula":"C\u003csub\u003e19\u003c/sub\u003eH\u003csub\u003e20\u003c/sub\u003eFNO\u003csub\u003e3\u003c/sub\u003e","MolecularWeight":"329.4 g/mol","Opticalactivity":"( - )","Pharmacodynamics":"Paroxetine treats the symptoms of depression, various anxiety disorders, posttraumatic stress disorder, obsessive-compulsive disorder, and the vasomotor symptoms of menopause via the inhibition of serotonin reuptake. The onset of action of paroxetine is reported to be approximately 6 weeks.  Due its serotonergic activity, paroxetine, like other SSRI drugs, may potentiate serotonin syndrome. This risk is especially high when monoamine oxidase (MAO) inhibitors are given within 2 weeks of paroxetine administration. Upon cessation of MAO inhibitors, a 2-week interval before paroxetine administration is recommended. Do not coadminister these agents.","Physical Description":"Solid","PrevSalts":["mesylate","maleate","acetate","hydrochloride"],"PubChemId":43815,"Record Description":["Paroxetine is a benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo. It has a role as an antidepressant, an anxiolytic drug, a serotonin uptake inhibitor, a hepatotoxic agent and a P450 inhibitor. It is a member of piperidines, a member of benzodioxoles, an organofluorine compound and an aromatic ether. It is functionally related to a monofluorobenzene. It is a conjugate base of a paroxetinium(1+).","Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.","Paroxetine is a Serotonin Reuptake Inhibitor. The mechanism of action of paroxetine is as a Serotonin Uptake Inhibitor.","Paroxetine is a selective serotonin reuptake inhibitor (SSRI) used in the therapy of depression, anxiety disorders and obsessive-compulsive disorder. Paroxetine therapy can be associated with transient asymptomatic elevations in serum aminotransferase levels and has been linked to rare instances of clinically apparent acute liver injury.","PAROXETINE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 8 approved and 25 investigational indications. This drug has a black box warning from the FDA.","Paroxetine hydrochloride and paroxetine mesylate belong to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize \u0026alpha;- or \u0026beta;-adrenergic, dopamine D\u003csub\u003e2\u003c/sub\u003e or histamine H\u003csub\u003e1\u003c/sub\u003e receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT\u003csub\u003e1A\u003c/sub\u003e and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT\u003csub\u003e1A\u003c/sub\u003e and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache (see Toxicity section below for a complete listing of side effects). Side effects generally occur during the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Paroxetine hydrochloride and mesylate are considered therapeutic alternatives rather than generic equivalents by the US Food and Drug Administration (FDA); both agents contain the same active moiety (i.e. paroxetine), but are formulated as different salt forms. Clinical studies establishing the efficacy of paroxetine in various conditions were performed using paroxetine hydrochloride. Since both agents contain the same active moiety, the clinical efficacy of both agents is thought to be similar. Paroxetine may be used to treat major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD) and premenstrual dysphoric disorder (PMDD). Paroxetine has the most evidence supporting its use for anxiety-related disorders of the SSRIs. It has the greatest anticholinergic activity of the agents in this class and compared to other SSRIs, paroxetine may cause greater weight gain, sexual dysfunction, sedation and constipation. ","A serotonin uptake inhibitor that is effective in the treatment of depression.","See also: Paroxetine Hydrochloride (has salt form); Paroxetine Mesylate (has salt form); Paroxetine Hydrochloride Hemihydrate (has salt form) ... View More ...","Paroxetine is a benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo. It has a role as an antidepressant, an anxiolytic drug, a serotonin uptake inhibitor, a hepatotoxic agent and a P450 inhibitor. It is a member of piperidines, a member of benzodioxoles, an organofluorine compound and an aromatic ether. It is functionally related to a monofluorobenzene. It is a conjugate base of a paroxetinium(1+).","LiverTox|CNS|Antidepressant|SSRI"],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Paroxetine","Name":"Paroxetine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q408471","Name":"Paroxetine","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00715","Name":"Paroxetine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/43815","Name":"Paroxetine","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL490","Name":"Paroxetine","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7936","Name":"Paroxetine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=61869-08-7","Name":"Paroxetine","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0014853","Name":"Paroxetine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07415","Name":"Paroxetine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/41VRH5220H","Name":"Paroxetine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID3023425","Name":"Paroxetine","Sub":false}]}],"SMILES":"C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4","Salts":["mesylate","maleate","acetate","hydrochloride"],"SaltsAcidCount":[0,1,0,2],"SaltsAmineCount":[1,1,1,2],"SaltsUNII":["M711N184JE","F726G2563Q","YPO0NTK49O","X2ELS050D8"],"Solubility":"Odorless, off-white powder, mp 147-150 °C . Solubility in water: \u003e1 g/mL/Paroxetine methanesulfonate/","StoreUNII":["41VRH5220H"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="107.781mm" version="1.2" viewBox="0 0 100.139 107.781" width="100.139mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="108.0" stroke="none" width="101.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="29.654" x2="14.423" y1="1.038" y2="1.038"/>
                  
            <line class="bond" id="mol1bnd2" x1="14.423" x2="8.92" y1="1.038" y2="10.576"/>
                  
            <line class="bond" id="mol1bnd3" x1="8.92" x2="14.423" y1="17.901" y2="27.439"/>
                  
            <line class="bond" id="mol1bnd4" x1="14.423" x2="29.654" y1="27.439" y2="27.439"/>
                  
            <line class="bond" id="mol1bnd5" x1="29.654" x2="37.27" y1="27.439" y2="14.239"/>
                  
            <line class="bond" id="mol1bnd6" x1="29.654" x2="37.27" y1="1.038" y2="14.239"/>
                  
            <path class="bond" d="M37.27 13.889v.7l16.531 1.899l-1.299 -2.249l1.299 -2.25z" fill="#000000" id="mol1bnd7" stroke="none"/>
                  
            <g class="bond" id="mol1bnd8">
                        
                <line x1="60.119" x2="52.502" y1="1.049" y2="14.239"/>
                        
                <line x1="61.527" x2="55.317" y1="3.488" y2="14.239"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd9" x1="60.119" x2="75.359" y1="1.049" y2="1.056"/>
                  
            <g class="bond" id="mol1bnd10">
                        
                <line x1="82.982" x2="75.359" y1="14.253" y2="1.056"/>
                        
                <line x1="80.166" x2="73.951" y1="14.253" y2="3.494"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd11" x1="82.982" x2="75.364" y1="14.253" y2="27.443"/>
                  
            <g class="bond" id="mol1bnd12">
                        
                <line x1="60.124" x2="75.364" y1="27.436" y2="27.443"/>
                        
                <line x1="61.532" x2="73.956" y1="24.998" y2="25.004"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd13" x1="52.502" x2="60.124" y1="14.239" y2="27.436"/>
                  
            <line class="bond" id="mol1bnd14" x1="82.982" x2="95.447" y1="14.253" y2="14.253"/>
                  
            <g class="bond" id="mol1bnd15">
                        
                <line x1="29.479" x2="29.829" y1="27.743" y2="27.136"/>
                        
                <line x1="30.603" x2="31.245" y1="30.194" y2="29.082"/>
                        
                <line x1="31.727" x2="32.66" y1="32.644" y2="31.028"/>
                        
                <line x1="32.851" x2="34.076" y1="35.095" y2="32.973"/>
                        
                <line x1="33.975" x2="35.491" y1="37.546" y2="34.919"/>
                        
                <line x1="35.098" x2="36.906" y1="39.997" y2="36.864"/>
                        
                <line x1="36.222" x2="38.322" y1="42.448" y2="38.81"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd16" x1="37.272" x2="31.626" y1="40.629" y2="50.413"/>
                  
            <line class="bond" id="mol1bnd17" x1="31.625" x2="37.276" y1="57.227" y2="67.011"/>
                  
            <g class="bond" id="mol1bnd18">
                        
                <line x1="52.516" x2="37.276" y1="67.011" y2="67.011"/>
                        
                <line x1="51.11" x2="38.685" y1="69.449" y2="69.449"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd19" x1="52.516" x2="60.145" y1="67.011" y2="80.204"/>
                  
            <g class="bond" id="mol1bnd20">
                        
                <line x1="52.533" x2="60.145" y1="93.398" y2="80.204"/>
                        
                <line x1="51.125" x2="57.329" y1="90.959" y2="80.206"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd21" x1="52.533" x2="37.293" y1="93.398" y2="93.398"/>
                  
            <g class="bond" id="mol1bnd22">
                        
                <line x1="29.665" x2="37.293" y1="80.204" y2="93.398"/>
                        
                <line x1="32.481" x2="38.7" y1="80.203" y2="90.959"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd23" x1="37.276" x2="29.665" y1="67.011" y2="80.204"/>
                  
            <line class="bond" id="mol1bnd24" x1="52.533" x2="60.105" y1="93.398" y2="101.752"/>
                  
            <line class="bond" id="mol1bnd25" x1="66.225" x2="76.657" y1="103.165" y2="98.523"/>
                  
            <line class="bond" id="mol1bnd26" x1="76.657" x2="75.471" y1="98.523" y2="87.328"/>
                  
            <line class="bond" id="mol1bnd27" x1="60.145" x2="71.429" y1="80.204" y2="82.634"/>
                  
            <g class="atom" id="mol1atm3">
                        
                <path d="M8.748 16.689h-.721l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .732v2.739h-.566v-4.9h.715l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.261 -.006 -.482v-2.768h.578v4.9z" fill="#3050F8" stroke="none"/>
                        
                <path d="M4.305 16.689h-.62v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.62v4.9z" fill="#3050F8" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M97.46 16.703h-.613v-4.899h2.732v.541h-2.119v1.739h1.994v.542h-1.994v2.077z" fill="#90E050" id="mol1atm13" stroke="none"/>
                  
            <path class="atom" d="M31.918 53.818q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.245 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.733 .0 1.233 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM28.054 53.818q.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.928 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .524 -.393 1.452z" id="mol1atm15" stroke="none"/>
                  
            <path class="atom" d="M65.036 104.697q-.0 .756 -.256 1.327q-.256 .566 -.756 .882q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.245 -.572 -.245 -1.334q.0 -.75 .245 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM61.172 104.697q.0 .923 .387 1.458q.393 .53 1.221 .53q.839 .0 1.22 -.53q.387 -.535 .387 -1.458q.0 -.929 -.387 -1.453q-.381 -.523 -1.208 -.523q-.834 -.0 -1.227 .523q-.393 .524 -.393 1.453z" id="mol1atm22" stroke="none"/>
                  
            <path class="atom" d="M77.316 83.412q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.245 -.571 -.245 -1.333q.0 -.75 .245 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM73.452 83.412q.0 .922 .387 1.458q.393 .53 1.221 .53q.839 .0 1.22 -.53q.387 -.536 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.834 .0 -1.227 .524q-.393 .524 -.393 1.453z" id="mol1atm24" stroke="none"/>
                
            <line class="hi" id="mol1bnd2" stroke="#3050F8" x1="8.92" x2="11.6715" y1="10.576" y2="5.807"/>
            <line class="hi" id="mol1bnd2" stroke="#3050F8" x1="8.92" x2="11.6715" y1="10.576" y2="5.807"/>
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="8.92" x2="11.6715" y1="17.901" y2="22.67"/>
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="8.92" x2="11.6715" y1="17.901" y2="22.67"/>
            <line class="hi" id="mol1bnd14" stroke="#90E050" x1="95.447" x2="89.2145" y1="14.253" y2="14.253"/>
            <line class="hi" id="mol1bnd16" stroke="#FF0D0D" x1="31.626" x2="34.449" y1="50.413" y2="45.521"/>
            <line class="hi" id="mol1bnd17" stroke="#FF0D0D" x1="31.625" x2="34.450500000000005" y1="57.227" y2="62.119"/>
            <line class="hi" id="mol1bnd24" stroke="#FF0D0D" x1="60.105" x2="56.319" y1="101.752" y2="97.57499999999999"/>
            <line class="hi" id="mol1bnd25" stroke="#FF0D0D" x1="66.225" x2="71.441" y1="103.165" y2="100.844"/>
            <line class="hi" id="mol1bnd26" stroke="#FF0D0D" x1="75.471" x2="76.064" y1="87.328" y2="92.9255"/>
            <line class="hi" id="mol1bnd27" stroke="#FF0D0D" x1="71.429" x2="65.787" y1="82.634" y2="81.419"/>
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"Antidepressive Agents, Second-Generation; Serotonin Uptake Inhibitors","Title":"Paroxetine","UNII":"41VRH5220H","Wikidata":"Q408471","Wikipedia":"Paroxetine","XLogP":3.5}